A review on the clinical pharmacokinetics of hydralazine.

IF 3.9 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2022-10-01 Epub Date: 2022-09-27 DOI:10.1080/17425255.2022.2129005

Asma Shahzad Qamar, Ammara Zamir, Sundus Khalid, Waseem Ashraf, Imran Imran, Iltaf Hussain, Anees Ur Rehman, Hamid Saeed, Abdul Majeed, Faleh Alqahtani, Muhammad Fawad Rasool

{"title":"A review on the clinical pharmacokinetics of hydralazine.","authors":"Asma Shahzad Qamar, Ammara Zamir, Sundus Khalid, Waseem Ashraf, Imran Imran, Iltaf Hussain, Anees Ur Rehman, Hamid Saeed, Abdul Majeed, Faleh Alqahtani, Muhammad Fawad Rasool","doi":"10.1080/17425255.2022.2129005","DOIUrl":null,"url":null,"abstract":"Introduction: Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. The current article reviews the clinical pharmacokinetics (PK) of hydralazine, which can be useful for clinicians in optimizing its dose and dosing frequency to avoid adverse effects and unexpected interactions that could risk patients' lives.Areas covered: This review has summarized the PK parameters for hydralazine after performing an extensive literature search. It includes 20 publications that were selected after applying eligibility criteria out of a pool of literature that was searched using Google Scholar, PubMed, Cochrane Central, and EBSCO databases. The included studies consisted of concentration vs. time profiles of hydralazine. If the PK data were not tabulated in the given study, the concentration vs. time profiles were scanned for the extraction of the PK data. The PK parameters were calculated by applying a non-compartmental analysis (NCA).Expert opinion: The current review will aid clinicians in understanding hydralazine PK in different disease populations. This clinical PK data might also be helpful in the development of a pharmacokinetic model of hydralazine.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":"18 10","pages":"707-714"},"PeriodicalIF":3.9000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Metabolism & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425255.2022.2129005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. The current article reviews the clinical pharmacokinetics (PK) of hydralazine, which can be useful for clinicians in optimizing its dose and dosing frequency to avoid adverse effects and unexpected interactions that could risk patients' lives.

Areas covered: This review has summarized the PK parameters for hydralazine after performing an extensive literature search. It includes 20 publications that were selected after applying eligibility criteria out of a pool of literature that was searched using Google Scholar, PubMed, Cochrane Central, and EBSCO databases. The included studies consisted of concentration vs. time profiles of hydralazine. If the PK data were not tabulated in the given study, the concentration vs. time profiles were scanned for the extraction of the PK data. The PK parameters were calculated by applying a non-compartmental analysis (NCA).

Expert opinion: The current review will aid clinicians in understanding hydralazine PK in different disease populations. This clinical PK data might also be helpful in the development of a pharmacokinetic model of hydralazine.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肼嗪的临床药动学研究进展。

简介:Hydralazine是一种血管扩张剂，用于治疗高血压、先兆子痫和心力衰竭。本文综述了肼嗪的临床药代动力学(PK)，这可以帮助临床医生优化其剂量和给药频率，以避免不良反应和可能危及患者生命的意外相互作用。涵盖领域:本综述在进行广泛的文献检索后总结了肼嗪的PK参数。它包括20篇出版物，这些出版物是从使用Google Scholar、PubMed、Cochrane Central和EBSCO数据库检索的文献池中应用资格标准后选出的。纳入的研究包括肼的浓度与时间分布。如果在给定的研究中没有列出PK数据，则扫描浓度与时间概况以提取PK数据。采用非区室分析(NCA)计算PK参数。专家意见:目前的综述将有助于临床医生了解肼嗪在不同疾病人群中的PK。这些临床药代动力学数据也可能有助于肼嗪药代动力学模型的建立。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Drug Metabolism & Toxicology 医学-生化与分子生物学

CiteScore

7.90

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data. Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug. The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.